



TED
ROGERS
SCHOOL
OF MANAGEMENT



Dexcom Inc. (NASDAQ: DXCM)

BUY Recommendation; Target Price: US\$160.8 (15.0% upside)

Healthcare
April 9th, 2024

Portfolio Manager: Nachiket Patel
Analysts: Kambeez Rahbar, Peter Nguyen, Emir Vohra, Mahtab Dulay

Table of Contents



Company Overview

Industry Analysis

Investment Theses

Risks & Mitigants

Valuation

Appendix

Executive Summary

Recommend a BUY with 15.0% Return



Company Metrics

Ticker	NASDAQ: DXCM
Share Price USD (As of 04/08/2024)	\$139.94
Beta (5Y)	1.21
Market Capitalization	\$53.56 B
Enterprise Value	\$53.43 B
52-Week High/Low	\$95.3 – \$142.0

Preview of Theses

1. Dexcom's Position in the CGM Market Leads the Way for Strong Organic Growth
2. Dexcom Brings the Power of CGM to the Masses with OTC Approval
3. Dexcom's Pure Play Efficiency Leading to Impressive Shareholder Returns

Historical Price Returns




Table of Contents



Company Overview

Industry Analysis

Investment Theses

Risks & Mitigants

Valuation

Appendix

Company Overview



Dexcom Inc. (NASDAQ: DXCM)

Company Outline


- Dexcom Inc. was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel and is headquartered in San Diego, CA.
- Medical device company that designs and develops CGMS (continuous glucose monitoring systems).
- Manufacturing facilities located in San Diego, California as well as Arizona.
- Dexcom began production at their new manufacturing site in Batu Kawan, Malaysia and have initiated construction of new facility in Galway, Ireland.

Revenue by Product


- Sensor & Other Revenue
- Hardware Revenue

Sensor Revenue: \$3.35 B

Hardware Revenue: \$371.0 M



Revenue by Region



■ US ■ International

No individual country other than United States generated revenue that represented more than 10% of Dexcom's total revenue.

Product Overview

	Most accurate CGM on the market
	60% smaller sensor than the G6
	All-in-one sensor and transmitter
	Cheaper alternative to the G7
	Simple and easy to use CGM system
	More accessible CGM

CGM is a wearable devices that track glucose levels continuously throughout the day. A CGM device has a tiny sensor that goes under the skin, usually on the belly or arm. The sensor measures glucose levels every few minutes and sends the data to a device to keep track of it.

Table of Contents



Company Overview

Industry Analysis

Investment Theses

Risks & Mitigants

Valuation

Appendix

Industry Analysis



Global Growth in Diabetes Markets to Outpace North America by 1-2% Per Year

Diabetes Around the World (2021 – 2031 CAGR)




Most Mature Device Market:
North America (38%)


Fastest Growing Device Market:
Asia-Pacific (14%)

Patient Growth in Dexcom Countries (2021 – 2023)


Japan Posted 4 Million Additional Diabetes Patients Annually



USD (\$B) Diabetes Devices Market (2022 – 2032)



Insulin Pumps Prescribed by Physicians in the US




Industry Analysis




Dexcom's Alignment with Growing Consumer Preferences

Consumer Preferences



33% of U.S. Consumers reported using wearable devices that explicitly monitor health issues, up from 28% in 2020.


Abbott vs. Dexcom Total U.S. Prescriptions Share



Isolating for Dexcom's largest competitor (Abbott), total prescription market share maintains an inverse relationship.

Dexcom's First Mover Advantage in the U.S. Market

- 1st approval of dedicated app to share glucose data with a caregiver.
- 1st to deliver single-digit MARD accuracy levels.
- 1st to enable users to monitor glucose levels on Apple Watch.
- 1st approval to send glucose data directly to smartphone.
- 1st Integrated CGM (iCGM) device, enabling integration with Automated Insulin Delivery (AID) systems.
- 1st clearance of real-time APIs expanding connectivity leadership.
- 1st CGM to connect directly to Apple Watch.



Over 70% of Prescriptions by PCPs

Patient's have a pre-existing preference towards Dexcom



Physicians have higher confidence choosing from a major provider



Better coverage by different insurances such as Medicare and Medicaid



Ease of use and higher reading accuracy



Table of Contents



Company Overview

Industry Analysis

Investment Theses

Risks & Mitigants

Valuation

Appendix



Thesis 1: The Best in the West

Dexcom's Position in the CGM Market Leads the Way for Strong Organic Growth

Strategic Partnerships

Continued Partnerships with Several Companies Providing



Personalization



Awareness



Coverage

G6 integrated with Garmin smartwatch and cycling computer through Dexcom app

HealthFleet's RestoreHealth app connects users to a live health coach to manage diabetes

Onduo's Highmark Insurance Provides Coverage for 7M Patients

Expansion of Coverage for G7 & Non-Insulin Users



Medicare expanded G7 coverage for Basal and non-insulin hypo (approved in 2023) which increased by coverage 2.5-fold.




Dexcom's G6 is fully covered under provincial plans and is in the process of transitioning into G7 which is covered by 50% of provincial plans.



Japan expanded coverage for all insulin-use products which include Dexcom's G6.

Market Potential with US Population Distribution



Dexcom G7 vs Competitors

	Abbott	Dexcom® CONTINUOUS GLUCE MONITORING	Medtronic
MARD	9.2%	8.2%	10.4%
Sensory Wear Time (Days)	14	10	7
Size	2.9mm	4.6mm	9.39mm
Warmup Time	1 hour	30 min	2 hours
Cost (monthly)	~ \$200	~ \$225	~ \$300

Sources: Dexcom Investor Presentation, Bloomberg, William Blair, Company Reports , DexCom Annual Report, McGill University, National Library of Medicine

Notes: (1) A 15 Day Sensory Time Is in Clinical Trial And Is Expected To Be Released In Early 2025 (2) Prices Are In CAD and Vary By Region



Thesis 2: Launch of Dexcom's Stelo

Dexcom Brings the Power of CGM to the Masses with OTC Approval

Stelo's Unique Qualities for Dexcom



First FDA Approved Over-The-Counter iCGM (18 Years+).




Built upon G7 platform to achieve volume efficiency in manufacturing and meet demand upon launch.



Currently follows a cash pay option vs. coverage by insurance and has contraindication for insulin patients.

FDA has stated that regulatory conditions for future OTC devices may require prior iCGM approval to maintain device accuracy.


Opportunity within T2 No Insulin & Prediabetic



Stelo / G7 / Lingo Comparison

	Dexcom Stelo	Dexcom G7	Abbott Lingo
Lifespan	15 Days	10 Days	14 Days
Use Case	Non-Insulin Diabetics	T1, T2 IIT, T2 Basal	Health & Wellness
Price	\$80 - \$90	\$88	\$80
Available OTC in USA	✓	✗	✗
Insurance Coverage	✗	✓	✗

Impact to Dexcom Revenue






Thesis 3: Pure Play Efficiency


Dexcom's Pure Play Efficiency Leading to Impressive Shareholder Returns

Increased Operational Efficiency


Product Platform Switch from G6 to G7



Manufacturing Expansion



Gross Margin



Operational Efficiency




Table of Contents



Company Overview

Industry Analysis

Investment Theses

Risks & Mitigants

Valuation

Appendix




Risks & Mitigants

Dexcom Faces General Common Risks but is Well Poised to Mitigate Them

Risks	Risk Impact & Mitigant
Competition	<ul style="list-style-type: none">Competitors like Medtronic and Abbott have FDA approval for continuous glucose monitors.Abbott is currently working on a new monitoring platform for Europe.Continued investment in R&D ensures a competitive edge and expanding product lines reduces reliance on a single product and market.
Manufacturing	<ul style="list-style-type: none">Dexcom operates and sells its products worldwide and is susceptible to issues related to manufacturing.With approval by the FDA in Dexcom's Stelo, the product could lead to more concerns in manufacturing.Initiation of production at the manufacturing site in Penang, Malaysia, as well as expansions to the Arizona site, will allow Dexcom to scale production capacity.
Reimbursement	<ul style="list-style-type: none">Dexcom may face reimbursement challenges due to limitations in insurance.Patients using Dexcom may need to navigate insurance approval processes for reimbursement.Over the past couple of years, coverage has been expanding; Medicare coverage was expanded in April 2023 to include individuals with diabetes who are on a type of insulin.

Impact & Probability





Catalysts

Setting Up for Long-Term Security

Dexcom ONE to G7 Form Factor

Smaller Form Factor Allows for Much More Opportunity

Like the G7, it is an all-in-one Sensor & Transmitter




New form factor will have an 60% reduction in sensor size. Testing is also underway to increase the sensor life from 10 to 15 days.


Expanding Global Availability of the Dexcom ONE

2024 Market Expansion of the Dexcom ONE

Expanded the Dexcom One to Spain, Belgium, Poland, and the Netherlands in the Q1 of 2024. More expansions to be announced in the near future to further target markets like Europe and Africa.



Transition to Direct Sales in Japan



Impact & Probability




Table of Contents



Company Overview

Industry Analysis

Investment Theses

Risks & Mitigants


Valuation

Appendix



Valuation: Comparable Company Analysis

EV/EBITDA is Trading at a Premium Relative to Comparable Universe at 39.11x



Valuation: Comparable Company Analysis



EV/EBITDA Base Case Scenario Projects 8% Upside, While EV/Revenue Projects 12.7% Upside

Comparable Commentary

- For our comparable selection criteria, we screened for EV/EBITDA multiple as our primary valuation multiple considering Dexcom's unique business model. Here we used the mean for our base case in which a premium factor was involved that determined Dexcom's premium relative to its industry from previous years.
- For our secondary multiple we used EV/Revenue where we used the mean multiple from the industry average and applied a similar premium factor as used in the EV/EBITDA approach.
- The companies that are selected for our Comparable analysis were filtered through similar business model and size and geographical exposure

EV/ EBITDA Relative Valuation

	Bear	Base	Bull
2024E EBITDA (M)	\$1,256	\$1,256	\$1,256
2024E EV/EBITDA (Premium)	35x	44.5x	52x
Implied Equity Value	\$43,830	\$55,762	\$65,182
Shares Outstanding	386	386	386
Equity Value / Share	\$113.55	\$144.46	\$168.87
Upside / Downside	(14.8%)	8.1%	26.6%

EV/ Revenue Valuation Sanity Check

	Bear	Base	Bull
2024E Revenue (M)	\$4,326	\$4,326	\$4,326
2024E EV/Revenue (Premium)	10x	13x	16x
Implied Equity Value	\$43,476	\$58,011	\$78,119
Shares Outstanding	386	386	386
Equity Value / Share	\$112.63	\$150.29	\$181.67
Upside / Downside	(15.5%)	12.7%	36.2%

3-Year Stock Performance Projections



Discounted Cash Flow Analysis

Valuation Approaches



Dexcom, Inc. Discounted Cash Flow Model (USD, Millions) - Unlevered Free Cashflows

Fiscal Year End Year	2023A	2024E	2025E	2026E	2027E	2028E
Total Revenue	\$3,622	\$4,132	\$4,772	\$5,391	\$6,282	\$7,051
% Revenue Growth YoY		14.1%	15.5%	13.0%	16.5%	12.3%
(-) Cost of Sales	(\$1,147)	(\$1,266)	(\$1,418)	(\$1,592)	(\$1,846)	(\$2,077)
(-) Other Operating Expenses	(\$1,691)	(\$1,890)	(\$2,135)	(\$2,359)	(\$2,687)	(\$2,947)
EBITDA	\$784	\$977	\$1,219	\$1,439	\$1,749	\$2,027
% EBITDA Margin	21.6%	23.6%	25.5%	26.7%	27.8%	28.7%
(-) Depreciation and Amortization	(\$186)	(\$242)	(\$252)	(\$257)	(\$265)	(\$243)
EBIT	\$598	\$734	\$966	\$1,182	\$1,484	\$1,784
(-) Tax (EBIT * Tax Rate)	(\$149)	(\$184)	(\$242)	(\$296)	(\$371)	(\$446)
NOPAT	\$448	\$551	\$725	\$887	\$1,113	\$1,338
% NOPAT Growth YoY		22.8%	31.6%	22.4%	25.5%	20.3%
(-) Capital Expenditures	(\$237)	(\$482)	(\$507)	(\$518)	(\$539)	(\$533)
(+) Depreciation and Amortization	\$186	\$242	\$252	\$257	\$265	\$243
(-) Change in Net Working Capital	(\$0)	(\$107)	(\$68)	(\$50)	(\$70)	(\$52)
Unlevered Free Cash Flow	\$397	\$205	\$402	\$576	\$769	\$996
Discount Period	0.73	1.73	2.73	3.73	4.73	
Weighted Average Cost of Capital	10.4%	10.4%	10.4%	10.4%	10.4%	10.4%
Discount Factor	0.93	0.84	0.76	0.69	0.63	
PV of Unlevered Free Cash Flow	\$190	\$339	\$440	\$531	\$623	
Terminal Value						\$90,198
PV of Terminal Value						\$56,438
Sum PV of FCF	\$58,390					

WACC Calculation

CAPM	Debt		
Risk Free Rate	4.25%	Long-term Debt	\$2,599.5
Beta	1.21	Cost of Debt	0.82%
Market Risk Premium	5.50%	Tax Rate	25.0%
Weight of Equity	95.30%	Weight of Debt	4.70%
Cost of Equity	10.91%	After Tax Cost of Debt	0.61%
Weighted Average Cost of Capital (ST)	10.42%		

Valuation Summary - EBITDA Multiple

PV of Forecast UFCF	\$2,123
EBITDA Exit Multiple	44.5x
PV of Terminal Value	\$56,438
Enterprise Value	\$58,561
(-) Total Debt	(\$2,600)
(+) Cash	\$2,724
Equity Value	\$58,686
Shares Outstanding	\$365
Equity Value per Share	\$160.78

Discounted Cash Flow Analysis

Valuation Approaches



Dexcom, Inc.						
Discounted Cash Flow Model (USD, Millions) - Unlevered Free Cashflows						
Fiscal Year End Year	2023A	2024E	2025E	2026E	2027E	2028E
Total Revenue	\$3,622	\$4,132	\$4,772	\$5,391	\$6,282	\$7,051
% Revenue Growth YoY	1	14.1%	15.5%	13.0%	16.5%	12.3%
(-) Cost of Sales	(\$1,147)	(\$1,266)	(\$1,418)	(\$1,592)	(\$1,846)	(\$2,077)
(-) Other Operating Expenses	(\$1,691)	(\$1,890)	(\$2,135)	(\$2,359)	(\$2,687)	(\$2,947)
EBITDA	\$784	\$977	\$1,219	\$1,439	\$1,749	\$2,027
% EBITDA Margin	21.6%	23.6%	25.5%	26.7%	27.8%	28.7%
(-) Depreciation and Amortization	(\$186)	(\$242)	(\$252)	(\$257)	(\$265)	(\$243)
EBIT	\$598	\$734	\$966	\$1,182	\$1,484	\$1,784
(-) Tax (EBIT * Tax Rate)	(\$149)	(\$184)	(\$242)	(\$296)	(\$371)	(\$446)
NOPAT	\$448	\$551	\$725	\$887	\$1,113	\$1,338
% NOPAT Growth YoY	3	22.8%	31.6%	22.4%	25.5%	20.3%
(-) Capital Expenditures	(\$237)	(\$482)	(\$507)	(\$518)	(\$539)	(\$533)
(+) Depreciation and Amortization	\$186	\$242	\$252	\$257	\$265	\$243
(-) Change in Net Working Capital	(\$0)	(\$107)	(\$68)	(\$50)	(\$70)	(\$52)
Unlevered Free Cash Flow	\$397	\$205	\$402	\$576	\$769	\$996
Discount Period		0.73	1.73	2.73	3.73	4.73
Weighted Average Cost of Capital		10.4%	10.4%	10.4%	10.4%	10.4%
Discount Factor		0.93	0.84	0.76	0.69	0.63
PV of Unlevered Free Cash Flow		\$190	\$339	\$440	\$531	\$623
Terminal Value						\$90,198
PV of Terminal Value						\$56,438
Sum PV of FCF		\$58,390				

1

- US Revenue growth is based on consensus patient growth rates now including Type 2 Diabetes – non-insulin patients from the Stelo multiplied by the expected market share (~ 55%)
- OUS revenue growth is based on consensus patient growth rates accounting for fluctuations in patient figures when expanding new markets

2

- Gross margin expansion to 63.5% to 67.1%, in 2024 and 2028, respectively due to product platform switch to G7 form factor as well as increased manufacturing capacity from plant expansion

3


- Capex figures show assumptions of plant construction in Ireland beginning as well as Arizona's plant expansion with possibility of further expansion when entering potential new markets

Discounted Cash Flow Analysis Assumptions



Various Case Scenarios

Implied Share Price Summary



	Scenario Analysis				
	Base	Low Expansion	Slower Adoption	Growing Globally	High Margin & Growth
Enterprise Value	\$58,561	\$46,711	\$49,652	\$65,204	\$71,006
(-) Total Debt	(\$2,600)	(\$2,604)	(\$2,599)	(\$2,600)	(\$2,600)
(+) Cash	\$2,724	\$2,724	\$2,724	\$2,724	\$2,724
Equity Value	\$58,686	\$46,830	\$49,778	\$65,328	\$71,130
Shares Outstanding	\$365	\$365	\$365	\$365	\$365
Equity Value per Share	\$160.78	\$128.3	\$136.4	\$179.0	\$194.9
Current Share Price	\$139.80	\$138.9	\$138.9	\$138.9	\$138.9
Implied Upside (%)	15.75%	(7.63%)	(1.82%)	28.86%	40.30%

Low Expansion	<ul style="list-style-type: none"> Decreased top line growth due market share dilution from increased product competition Higher cost of plant expansion as well as cost of production increasing
Slower Adoption	<ul style="list-style-type: none"> Decreased top line growth due market share dilution from increased product competition
Growing Globally	<ul style="list-style-type: none"> Increased market share globally with G7 and Dexcom One Increased type 2 non-insulin patient purchases of Stelo
High Margin & Growth	<ul style="list-style-type: none"> Increased global revenues from product market penetration Margin expansion from increased manufacturing facilities and new product platform

Sensitivity Analysis – Discounted Cash Flow Analysis



Target Price: EBITDA Exit Multiple vs WACC

	41.0x	42.0x	43.0x	44.5x	45.0x	46.0x	47.0x
8.00%	\$165	\$169	\$173	\$178	\$180	\$184	\$188
8.50%	\$161	\$165	\$169	\$175	\$176	\$180	\$184
9.00%	\$158	\$162	\$165	\$171	\$173	\$176	\$180
10.42%	\$149	\$152	\$156	\$161	\$163	\$166	\$169
11.00%	\$145	\$148	\$152	\$157	\$159	\$162	\$165
11.50%	\$142	\$145	\$149	\$154	\$155	\$159	\$162
12.00%	\$139	\$142	\$146	\$150	\$152	\$155	\$159

Implied Upside: EBITDA Exit Multiple vs WACC

	41.0x	42.0x	43.0x	44.5x	45.0x	46.0x	47.0x
8.00%	18.7%	21.5%	24.2%	28.4%	29.8%	32.6%	35.3%
8.50%	16.1%	18.9%	21.6%	25.7%	27.0%	29.7%	32.5%
9.00%	13.7%	16.3%	19.0%	23.0%	24.3%	27.0%	29.6%
10.42%	7.0%	9.5%	12.0%	15.8%	17.0%	19.5%	22.0%
11.00%	4.5%	6.9%	9.3%	13.0%	14.2%	16.7%	19.1%
11.50%	2.3%	4.7%	7.1%	10.7%	11.9%	14.2%	16.6%
12.00%	0.2%	2.5%	4.9%	8.4%	9.5%	11.9%	14.2%

Target Price: Revenue Growth vs Gross Margin Growth

	(4%)	(2%)	(1%)	0%	1%	2%	4%
3%	\$126	\$137	\$143	\$149	\$156	\$163	\$177
2%	\$131	\$142	\$149	\$155	\$162	\$169	\$183
1%	\$133	\$145	\$151	\$158	\$165	\$172	\$187
0%	\$135	\$148	\$154	\$161	\$168	\$175	\$190
(1%)	\$138	\$150	\$157	\$164	\$171	\$178	\$193
(2%)	\$140	\$153	\$160	\$167	\$174	\$181	\$197
(3%)	\$145	\$158	\$165	\$172	\$180	\$187	\$204

Implied Upside: Revenue Growth vs Gross Margin Growth


	(4%)	(2%)	(1%)	0%	1%	2%	4%
3%	(9.5%)	(1.3%)	3.1%	7.6%	12.2%	17.0%	27.1%
2%	(6.0%)	2.5%	7.0%	11.7%	16.5%	21.5%	32.0%
1%	(4.3%)	4.4%	9.0%	13.7%	18.6%	23.7%	34.4%
0%	(2.6%)	6.3%	11.0%	15.8%	20.8%	26.0%	36.9%
(1%)	(0.8%)	8.2%	12.9%	17.8%	22.9%	28.2%	39.3%
(2%)	0.9%	10.1%	14.9%	19.9%	25.1%	30.4%	41.7%
(3%)	4.4%	13.8%	18.8%	24.0%	29.4%	34.9%	46.6%



Recommendation

Share Price Results in a Target Price of \$160.8, Implying Upside of 15%

Valuation Football Field



Theses Recap

- 1 Position in the CGM Market Leads the Way for Strong Organic Growth
- 2 Bringing Power of CGM to the Masses with OTC Approval
- 3 Pure Play Efficiency Leading to Impressive Shareholder Returns

Street vs. TRIC (\$)




Table of Contents



Company Overview

Industry Analysis

Investment Theses

Risks & Mitigants

Valuation

Appendix

Appendix

Income Statement



Income Statement (USD mm)	2021A	2022A	2023A	2024E	2025E	2026E	2027E	2028E
Revenues								
United States	1,849	2,142	2,625	2,934	3,257	3,593	3,926	4,251
International	599	768	997	1,198	1,515	1,798	2,355	2,801
Total Revenues	2,449	2,910	3,622	4,132	4,772	5,391	6,282	7,051
COS (excl. Depreciation & Amortization of PPE)	666	871	1,147	1,266	1,418	1,592	1,846	2,077
Depreciation and amortization of PPE	102	156	186	242	252	257	265	243
Gross Profit	1,681	1,883	2,289	2,624	3,102	3,542	4,171	4,731
R&D	517	484	506	567	644	715	819	903
Collaborative R&D Fee	87	-	-	-	-	-	-	-
SG&A	811	1,008	1,185	1,322	1,491	1,644	1,869	2,045
Total Operating Expenses	1,415	1,492	1,691	1,890	2,135	2,359	2,687	2,947
Operating Income	266	391	598	734	966	1,182	1,484	1,784
Other income (expense), net	(9)	(0)	113	49	77	54	78	172
EBT	257	391	710	783	1,043	1,236	1,562	1,956
Income Tax	40	50	169	196	261	309	391	489
Net income	\$ 217	\$ 341	\$ 542	\$ 587	\$ 783	\$ 927	\$ 1,172	\$ 1,467
Shares Outstanding								
Shares outstanding, basic	387	389	386	386	386	386	386	386
Shares outstanding, diluted	429	428	426	426	426	426	426	426
EPS								
Basic EPS	0.56	0.88	1.40	1.52	2.03	2.40	3.04	3.80
Diluted EPS	0.51	0.80	1.27	1.38	1.84	2.18	2.75	3.45
EBITDA Reconciliation								
EBIT	266	391	598	734	966	1,182	1,484	1,784
Depreciation & Amortization	102	156	186	242	252	257	265	243
EBITDA	368	547	784	977	1,219	1,439	1,749	2,027
Gross margin	69%	65%	63%	64%	65%	66%	66%	67%
EBIT Margin	11%	13%	17%	18%	20%	22%	24%	25%
EBITDA Margin	15%	19%	22%	24%	26%	27%	28%	29%
NI margin	9%	12%	15%	14%	16%	17%	19%	21%

Appendix

Balance Sheet



Balance Sheet (USD mm)	2021A	2022A	2023A	2024E	2025E	2026E	2027E	2028E
Assets								
Cash and cash equivalents	1,052.6	642.3	566.3	413.2	477.2	1,769.1	628.2	705.1
Short-term marketable securities	1,678.6	1,813.9	2,157.8	2,735.0	2,142.7	2,935.1	5,170.9	5,253.9
Accounts receivable	514.3	713.3	973.9	994.6	1,151.7	1,301.1	1,516.1	1,697.2
Inventories	357.3	306.7	559.6	579.2	650.5	730.6	846.7	950.3
Prepaid expenses and other current assets	81.6	192.6	168.3	180.3	203.8	225.2	256.5	281.3
Total current assets	3,684.4	3,668.8	4,425.9	4,902.3	4,626.0	6,961.0	8,418.3	8,887.9
Property, plant & equipment, net	801.8	1,055.6	1,113.1	1,395.3	1,718.3	2,032.3	2,369.5	2,675.7
Operating lease right-of-use assets	88.1	80.0	71.4	69.1	66.3	63.0	59.2	54.8
Goodwill	26.5	25.7	25.2	25.2	25.2	25.2	25.2	25.2
Intangibles, net	31.5	173.3	134.5	99.3	66.7	35.8	7.2	-
Deferred tax assets	290.5	341.2	419.4	419.4	419.4	419.4	419.4	419.4
Other assets	10.5	47.1	75.0	58.6	65.5	74.0	86.2	96.8
Total assets	4,933.3	5,391.7	6,264.5	6,971.1	6,987.4	9,610.8	11,385.0	12,159.7
Liabilities & Shareholders' equity								
Accounts payable and accrued liabilities	573.0	901.8	1,345.5	1,291.2	1,450.4	1,628.8	1,887.7	2,118.7
Accrued payroll and related expenses	125.2	134.3	171.0	176.1	199.0	219.9	250.5	274.7
Short-term operating lease liabilities	20.5	20.5	21.1	13.0	16.0	18.9	22.1	24.9
ST - Deferred revenue	2.1	10.1	18.4	13.0	15.0	16.9	19.7	22.1
Total current liabilities	720.8	1,839.3	1,556.0	1,493.3	1,680.4	1,884.5	2,180.0	2,440.4
Long-term senior convertible notes	1,981.8	1,197.7	2,434.2	2,443.3	1,240.5	2,476.8	2,484.4	1,239.6
Long-term operating lease liabilities	98.6	94.6	80.1	56.8	69.9	82.7	96.4	108.9
Other long-term liabilities	90.0	128.3	125.6	156.4	182.5	208.5	237.7	264.7
Total liabilities	2,891.2	3,259.9	4,195.9	4,149.8	3,173.3	4,652.5	4,998.5	4,053.6
Shareholders' equity								
Common shares	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Additional paid-in capital	2,108.7	2,258.1	3,514.6	3,680.1	3,866.5	4,072.9	4,308.4	4,567.4
Accumulated OCI	0.5	(11.6)	(16.7)	(16.7)	(16.7)	(16.7)	(16.7)	(16.7)
Retained earnings	138.7	479.9	1,021.4	1,608.6	2,391.2	3,318.4	4,489.9	5,956.7
Treasury stock	(206.2)	(595.0)	(2,451.1)	(2,451.1)	(2,451.1)	(2,451.1)	(2,451.1)	(2,451.1)
Total equity	2,042.1	2,131.8	2,068.6	2,821.3	3,790.3	4,923.8	6,330.9	8,056.6
Liabilities & Shareholders' equity	4,933.3	5,391.7	6,264.5	6,971.1	6,987.4	9,610.8	11,385.0	12,159.7

Source(s): CapIQ, Kroll, Team Analysis

Appendix

Cashflow Statement



Statement of Cash Flows (USD mm)	2024E	2025E	2026E	2027E	2028E
<u>Operating activities</u>					
Net income	587	783	927	1,172	1,467
Adjustments to Net Income and Non-Cash Charges:					
(+)Depreciation and Amortization	242	252	257	265	243
(+)SBC	165	186	206	235	259
(+)Non-Cash Interest Expense	8	7	6	8	5
Changes in operating assets and liabilities:					
Changes in working capital	(107)	(68)	(50)	(70)	(52)
Addition to Operating Lease Right of Use Assets	(6)	(7)	(8)	(9)	(11)
Repayments of Operating Lease Liabilities	(31)	-	-	-	-
Additions in Operating lease liabilities	-	16	16	17	15
Other Non-Current Assets	16	(7)	(8)	(12)	(11)
Other Non-Current Liabilities	31	26	26	29	27
Operating cash flow	906	1,189	1,372	1,634	1,943
<u>Investing activities</u>					
(-) Purchases of Property and Equipment	(482)	(507)	(518)	(539)	(533)
Investing cash flow	(482)	(507)	(518)	(539)	(533)
<u>Financing activities</u>					
Proceeds from issuance of convertible notes, net of issuance costs	-	-	1,230	-	-
Repayments of Notes	-	(1,210)	-	-	(1,250)
(-) Purchase of Marketable Securities	(577)	-	(792)	(2,236)	(83)
(+)Proceeds from sale and maturity of marketable securities	-	592	-	-	-
Financing cash flows	(577)	(618)	438	(2,236)	(1,333)
Net Change in Cash	(153)	64	1,292	(1,141)	77

Management Overview



Management & Directors



Kevin Sayer: President, CEO and Chairman

- Appointed to CEO in 2015 and Chairman of the Board in 2018.
- Kevin began his career at Dexcom as a member of the Board of Directors in 2007.
- Before Dexcom, Kevin held various management positions including VP and GM of Medtronic MiniMed.



Teri Lawver: CCO and EVP

- Teri joined Dexcom in 2023, she has 30 years of experience in the healthcare industry.
- Most recently Teri was Worldwide Vice President, Immunology at a subsidiary of J&J where she grew annual revenue by more than 45%.



Jacob Leach: COO and EVP


- Jacob joined Dexcom in 2004.
- Became COO and EVP in 2022, prior to his promotion Jacob served as CTO where he led technology development at the firm.
- Jacob's team developed the first commercial Dexcom CGM device.



Jereme Sylvain: CFO and EVP

- Appointed as CFO in 2018, Jereme oversees investor relations as well as Dexcom's finance organization.
- Initially joined Dexcom in 2018 as VP of Finance and Corporate Controller.

Top Holdings



Competitor Profile




Abbott Laboratories

Company Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.


1-Year Price-Volume Chart



Company Metrics


Ticker	NYSE: ABT
Share Price	\$112.02
Shares Outstanding	1,735 M
Revenue Growth (%)	(8.12%)
Market Capitalization (\$M)	\$194,375 M
Debt (\$M)	\$15,873 M
Enterprise Value (\$M)	\$203,193 M
Cash & Short-Term Investments (\$M)	\$7,279 M

Revenue by Segment



Revenue Breakdown

Revenue by Geography



Competitor Profile


ResMed Inc.



Company Description

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.


1-Year Price-Volume Chart



Company Metrics

Ticker	NYSE: RMD
Share Price	\$184.36
Shares Outstanding	146 M
Revenue Growth (%)	18.02%
Market Capitalization (\$M)	\$27,078 M
Debt (\$M)	\$1,391 M
Enterprise Value (\$M)	\$28,252 M
Cash & Short-Term Investments (\$M)	\$217 M

Revenue Breakdown



Competitor Profile


Insulet Corporation



Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.


1-Year Price-Volume Chart




Company Metrics

Ticker	NASDAQ: PODD
Share Price	\$164.05
Shares Outstanding	69 M
Revenue Growth (%)	30.02%
Market Capitalization (\$M)	\$11,471 M
Debt (\$M)	\$1,448 M
Enterprise Value (\$M)	\$12,215 M
Cash & Short-Term Investments (\$M)	\$704 M

Revenue by Segment



Revenue by Geography



■ Omnipod Products ■ Drug Delivery

■ US ■ International

Competitor Profile


Medtronic



Company Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company operates segments in Cardiovascular, Neuroscope, Medical Surgical, Diabetes Group. The company was founded in 1949 and is headquartered in Dublin, Ireland. short

1-Year Price-Volume Chart




Company Metrics

Ticker NYSE: MDT


Share Price	\$85.00
Shares Outstanding	1327 M
Revenue Growth (%)	5.0%
Market Capitalization (\$M)	\$112,864 M
Debt (\$M)	\$25,182 M
Enterprise Value (\$M)	\$35,534 M
Cash & Short-Term Investments (\$M)	\$8,321 M

Revenue by Segment



- Cardiovascular
- Neuroscope
- Medical Surgical
- Diabetes Group

Revenue by Geography



- United States
- Rest of The World

Competitor Profile


Sensonics Holdings Inc.



Company Description

Sensonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor,. Sensonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.


1-Year Price-Volume Chart



Company Metrics

Ticker	NYSEAM: SENS
Share Price	\$0.50
Shares Outstanding	530.7 M
Revenue Growth (%)	16.3%
Market Capitalization (\$M)	\$266.7 M
Debt (\$M)	\$47.8 M
Enterprise Value (\$M)	\$246.1 M
Cash & Short-Term Investments (\$M)	\$109.5 M

Revenue Breakdown



Competitor Profile

Roche Holding AG




Company Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in several regions. The company offers pharmaceutical products in therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. Recently Roche released Accu-Chek, a CGM using predictive AI to base results. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.


Company Metrics

Ticker	SWX: ROG
Share Price	\$243.23
Shares Outstanding	797 M
Revenue Growth (%)	1.34%
Market Capitalization (\$M)	\$195,448 M
Debt (\$M)	\$34,138 M
Enterprise Value (\$M)	\$222,324 M
Cash & Short-Term Investments (\$M)	\$11,631 M

1-Year Price-Volume Chart



Revenue Breakdown



Competitor Profile

Becton, Dickinson & Company



Company Description

Founded in 1897 Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Company Metrics


Ticker	NYSE: BDX
Share Price	\$241.72
Shares Outstanding	288 M
Revenue Growth (%)	4.00%
Market Capitalization (\$M)	\$71,119 M
Debt (\$M)	\$16,110 M
Enterprise Value (\$M)	\$86,047 M
Cash & Short-Term Investments (\$M)	\$1,182 M

1-Year Price-Volume Chart




Revenue Breakdown

Revenue by Segment



Revenue by Geography



- United States 57%
- Europe, The Middle East and Africa (EMEA) 22%
- Greater Asia 15%
- Other 6%


- BD Medical (Excl. of BD Interventional) 49%
- BD Life Sciences 27%
- BD Interventional 24%

Appendix


Patents



Patents Active vs Expired




G4 Patents Until Expiry



G4 patents are used within Dexcom's recent CGM models including G5 and G6

Patents Filed By Year





Product Specification


Science Behind Continuous Glucose Monitoring

Historical Method of Measuring Blood Glucose

-  Receive reminder via numerous alarms set throughout the day
-  "Finger-prick" a small amount of blood onto a test strip that can be read by a blood glucose monitor (BGM)
-  Take note of blood glucose levels to ensure it is within range and can reasonably remain within range

Provides a snapshot of glucose levels at a single point in time and offers no insight into fluctuations of levels through the day.

Flow of Blood Glucose to Interstitial Fluid



Benefits of Continuous Glucose Monitoring

Shows current glucose level and **predicts direction that glucose** is heading and rate of change, additionally provides alerts when out of range.

If integrated with an insulin pump, may be able to pause or adjust **insulin delivery** in response to changes in glucose levels

Ability to **share glucose levels** with a family member and/or healthcare team automatically

Limitations of Continuous Glucose Monitoring

At rest, the interstitial glucose lags about **5 minutes behind the blood glucose**; in situations when glucose changes rapidly, such as during exercise, **lag time increases up to 24 minutes**.

Alarm fatigue – the condition in which device users are repeatedly bothered by frequent and/or false alarms.



Information overload – often CGM trainers suggest spending the first week on CGM just watching the output without making changes

Appendix


GLP Impact on CGM




Flow of Blood Glucose to Interstitial Fluid



Flow of Blood Glucose to Interstitial Fluid



Clinical Drivers of GLP-1 Use with CGM






Appendix

Operations and Medicare Enrollment

Medicare Enrollment Growth



Leased Manufacturing Properties

Location	Leases Expiration Date
San Diego, California	2028
Mesa, Arizona	2030
Penang, Malaysia	2082

Dexcom has renewal options that would extend the lease expiring in 2028 for four additional five-year terms and lease expiring in 2030 for two additional five-year terms.

Operations


- Majority of operations are conducted in San Diego, Arizona, and Malaysia
- Dexcom manufactures their current CGM systems with certain components supplied by outside vendors and other components are manufactured internally
- Dexcom relies on single and/or sole sources for certain components and materials used in manufacturing, such as for the application-specific integrated circuit that is incorporated into the transmitter and certain polymers used to synthesize the polymeric bio interface membranes for their products



Market Penetration

Growth Of Different Diabetic Distribution

Market Penetration For Diabetic Distribution 2022 vs 2025



Average Selling Price	Penetration				
	3%	4%	5%	10%	15%
2125	1274	1699	2124	4248	6372
1750	1050	1400	1750	3500	5250
1500	900	1200	1500	3000	4500

Average Selling Prices Based on various CGM's on the market including G7, Libre 3, Guardian 4, Eversense 3

Company Comparable Analysis

EV/EBITDA Premium Analysis



Date	Dexcom	Abbott	ResMed	Insulet Corp	Medtronic	Roche Holding	Industry	Dexcom Premium (% of industry)
Feb-28-2020	125.49	18.36	28.22	151.73	15.33	10.91	58.34	215%
Mar-31-2020	109.17	18.77	26.25	133.15	13.90	11.07	52.05	210%
Apr-30-2020	127.50	22.14	25.77	159.66	14.92	11.83	60.30	211%
May-29-2020	137.03	22.76	26.63	157.76	18.02	11.75	62.33	220%
Jun-30-2020	135.66	22.00	31.55	162.30	17.07	11.56	63.36	214%
Jul-31-2020	143.37	25.52	33.21	169.58	17.87	11.58	66.86	214%
Aug-31-2020	121.92	27.58	29.24	136.05	23.48	11.58	58.31	209%
Sep-30-2020	112.64	27.43	27.78	147.43	22.61	11.57	58.24	193%
Oct-30-2020	107.01	25.82	29.14	138.53	21.95	10.85	55.55	193%
Nov-30-2020	82.75	26.31	31.75	141.57	25.82	11.01	53.20	156%
Dec-31-2020	87.41	25.78	32.19	140.42	26.47	11.35	53.94	162%
Jan-29-2021	91.54	25.08	29.31	146.76	25.28	11.33	54.88	167%
Feb-26-2021	100.74	24.45	28.06	153.61	26.92	10.79	57.43	175%
Mar-31-2021	89.10	24.46	28.24	154.68	27.74	11.13	55.89	159%
Apr-30-2021	98.04	21.47	27.19	175.21	30.47	10.87	60.54	162%
May-28-2021	82.66	20.36	29.72	144.71	24.24	11.43	52.19	158%
Jun-30-2021	96.38	20.24	35.50	147.27	21.78	12.71	55.65	173%
Jul-30-2021	105.80	18.89	39.08	150.02	22.92	13.40	58.35	181%
Aug-31-2021	110.55	19.51	40.63	161.85	20.26	14.05	61.14	181%
Sep-30-2021	119.26	18.29	36.90	154.61	19.45	13.12	60.27	198%
Oct-29-2021	118.65	18.35	35.38	168.37	18.67	13.53	62.16	191%
Nov-30-2021	125.71	18.22	34.31	148.12	15.64	13.62	59.27	212%
Dec-31-2021	110.52	19.72	35.17	136.87	15.33	13.45	55.18	200%
Jan-31-2022	90.16	18.21	30.48	127.79	15.33	12.67	49.11	184%
Feb-28-2022	91.53	16.92	32.86	99.35	15.09	12.44	44.70	205%
Mar-31-2022	103.74	16.62	32.31	99.97	16.30	12.99	46.99	221%
Apr-29-2022	111.89	15.12	26.31	90.08	15.42	12.82	45.27	247%
May-31-2022	75.22	15.53	26.76	72.64	15.28	11.73	36.19	208%
Jun-30-2022	66.76	14.41	27.58	74.09	13.67	11.49	34.67	193%
Jul-29-2022	73.65	14.08	31.57	83.79	14.04	11.85	38.16	193%
Aug-31-2022	79.85	13.11	28.53	114.42	13.43	11.77	43.52	183%
Sep-30-2022	78.61	12.38	28.33	103.19	13.16	12.07	41.29	190%
Oct-31-2022	89.87	13.43	28.71	115.86	14.11	12.42	45.73	197%
Nov-30-2022	94.32	13.84	29.53	163.06	12.33	11.59	54.11	174%
Dec-30-2022	95.31	14.12	26.83	160.44	13.26	11.00	53.49	178%
Jan-31-2023	89.58	16.58	29.18	156.71	14.15	10.71	52.82	170%
Feb-28-2023	81.25	14.51	27.31	148.20	13.56	9.61	49.07	166%
Mar-31-2023	77.80	14.45	28.04	170.17	14.39	9.24	52.35	149%
Apr-28-2023	80.68	17.64	28.79	170.06	15.98	9.90	53.84	150%
May-31-2023	78.86	16.30	25.33	157.23	13.84	10.14	50.28	157%
Jun-30-2023	83.86	17.38	26.24	165.00	15.58	9.67	52.96	158%
Jul-31-2023	86.43	19.20	26.68	158.61	15.53	10.35	52.80	164%
Aug-31-2023	67.59	17.80	18.82	93.84	14.60	9.98	37.11	182%
Sep-29-2023	59.74	16.80	17.51	78.89	14.12	9.66	32.79	182%
Oct-31-2023	50.64	16.70	16.50	66.40	12.91	9.06	28.70	176%
Nov-30-2023	56.45	18.08	18.32	84.05	14.03	9.14	33.35	169%
Dec-29-2023	66.22	19.04	19.89	95.75	14.51	9.44	37.48	177%
Jan-31-2024	68.82	20.67	20.89	84.80	15.29	9.52	36.67	188%
Feb-29-2024	58.37	19.84	19.16	38.48	14.27	9.93	26.68	219%
Mar-28-2024	62.44	19.04	21.69	40.11	14.83	9.85	27.99	223%
Apr-04-2024	64.28	18.47	20.32	38.31	14.35	9.66	27.57	233%

Company Comparable Analysis

EV/Revenue Premium Analysis



Date	Dexcom	Abbott	ResMed	Insulet Corp	Medtronic	Sensomics	Roche Holding	Industry	Dexcom Premium (% of industry)
Feb-28-2020	16.87	4.73	8.69	16.90	4.83	12.68	4.23	9.85	171%
Mar-31-2020	16.46	4.84	8.08	14.83	4.37	7.16	4.29	8.58	192%
Apr-30-2020	19.13	5.54	8.17	17.78	4.70	6.90	4.59	9.54	200%
May-29-2020	21.62	5.69	8.44	16.64	5.06	5.98	4.56	9.71	223%
Jun-30-2020	23.18	5.50	10.00	17.12	4.77	7.66	4.49	10.39	223%
Jul-31-2020	23.87	6.14	10.53	17.88	4.99	8.78	4.54	10.96	218%
Aug-31-2020	23.30	6.64	9.14	17.43	5.74	11.24	4.54	11.15	209%
Sep-30-2020	22.56	6.60	8.68	18.89	5.57	10.02	4.53	10.98	205%
Oct-30-2020	16.42	6.24	9.44	17.75	5.41	9.77	4.25	9.90	166%
Nov-30-2020	16.43	6.39	10.28	19.61	6.06	12.89	4.32	10.85	151%
Dec-31-2020	19.07	6.26	10.43	19.46	6.23	25.13	4.45	13.00	147%
Jan-29-2021	19.34	6.52	9.72	20.33	5.95	85.26	4.44	21.65	89%
Feb-26-2021	19.41	6.51	9.30	19.07	6.21	130.99	4.34	27.98	69%
Mar-31-2021	17.49	6.51	9.36	19.21	6.27	211.18	4.47	39.21	45%
Apr-30-2021	18.05	6.04	9.05	21.76	6.89	192.90	4.37	37.01	49%
May-28-2021	17.25	5.83	9.89	18.87	6.18	98.34	4.59	22.99	75%
Jun-30-2021	20.00	5.79	11.81	19.20	6.09	196.51	5.11	37.79	53%
Jul-30-2021	22.67	5.60	13.00	19.56	6.41	154.05	5.11	32.34	70%
Aug-31-2021	23.29	5.81	13.39	20.99	6.17	156.18	5.36	33.03	71%
Sep-30-2021	24.06	5.45	12.16	20.05	5.83	130.59	5.00	29.02	83%
Oct-29-2021	25.69	5.63	11.63	21.83	5.59	135.13	5.16	30.09	85%
Nov-30-2021	23.16	5.47	11.28	19.59	4.99	97.52	5.20	23.89	97%
Dec-31-2021	22.09	5.92	11.56	18.11	4.85	82.05	5.13	21.39	103%
Jan-31-2022	17.64	5.28	9.89	16.90	4.85	82.38	4.83	20.25	87%
Feb-28-2022	16.06	5.15	10.66	17.12	4.88	53.42	4.66	15.99	100%
Mar-31-2022	19.93	5.06	10.48	17.23	5.12	58.12	4.87	17.26	115%
Apr-29-2022	15.37	4.70	8.44	15.53	4.85	38.83	4.81	13.22	116%
May-31-2022	11.15	4.83	8.58	13.58	4.64	34.58	4.40	11.68	95%
Jun-30-2022	11.16	4.48	8.84	13.85	4.22	30.05	4.31	10.99	102%
Jul-29-2022	11.82	4.39	10.12	15.67	4.34	39.10	4.52	12.85	92%
Aug-31-2022	11.84	4.12	9.18	15.65	4.15	54.40	4.49	14.83	80%
Sep-30-2022	11.60	3.89	9.11	14.11	3.92	38.81	4.60	12.29	94%
Oct-31-2022	16.62	4.02	9.24	15.84	4.20	34.07	4.74	12.68	131%
Nov-30-2022	16.00	4.32	9.50	17.27	3.91	29.68	4.42	12.16	132%
Dec-30-2022	15.58	4.40	8.63	16.99	3.85	27.10	4.20	11.54	135%
Jan-31-2023	14.73	4.57	9.36	16.60	4.11	30.33	4.09	11.97	123%
Feb-28-2023	14.64	4.23	8.76	15.30	4.14	27.42	3.62	11.16	131%
Mar-31-2023	15.32	4.21	9.00	17.57	4.04	18.15	3.48	10.25	149%
Apr-28-2023	15.42	4.82	9.19	17.56	4.49	14.78	3.72	10.00	154%
May-31-2023	14.90	4.46	8.08	14.54	4.06	13.80	3.81	9.09	164%
Jun-30-2023	16.34	4.75	8.37	15.26	4.31	17.07	3.64	9.96	164%
Jul-31-2023	15.03	5.00	8.51	14.67	4.30	20.86	3.82	10.31	146%
Aug-31-2023	12.17	4.66	5.88	9.64	3.98	11.33	3.68	7.33	166%
Sep-29-2023	11.23	4.40	5.47	8.10	3.85	15.04	3.56	7.38	152%
Oct-31-2023	9.93	4.33	5.04	6.82	3.52	11.89	3.34	6.41	155%
Nov-30-2023	12.96	4.75	5.59	8.99	3.85	13.61	3.37	7.59	171%
Dec-29-2023	13.94	5.00	6.07	10.24	3.98	13.08	3.48	7.97	175%
Jan-31-2024	13.62	5.12	6.47	9.07	4.19	12.87	3.51	7.84	174%
Feb-29-2024	12.21	5.35	5.93	7.20	3.95	15.54	3.49	7.67	159%
Mar-28-2024	14.73	5.14	6.72	7.50	4.11	11.51	3.46	7.60	194%
Apr-04-2024	14.16	4.98	6.29	7.17	3.97	10.64	3.39	7.23	196%

Company Comparable Analysis

Full Valuation Analysis



EV/EBITDA

	Bear	Base	Bull
Dexcom NTM EBITDA (M)	1,256	1,256	1,256
Peer average EV/EBITDA	20.0x	20.0x	20.0x
Dexcom EV/EBITDA Premium Over Peers	75.0%	122.5%	160.0%
Dexcom NTM EV/EBITDA	35.0x	44.5x	52.0x
Dexcom TEV	\$43,960	\$55,892	\$65,312
Subtract: Net debt	\$130	\$130	\$130
Implied Equity Value	\$43,830	\$55,762	\$65,182
Shares Outstanding	386.0	386.0	386.0
Implied Share Price	\$113.55	\$144.46	\$168.87
Current Share Price	133.34	133.34	133.34
Implied Upside/(Downside)	(14.8%)	8.1%	26.6%

EV/REVENUE

	Bear	Base	Bull
Dexcom NTM Revenue (M)	4,326	4,326	4,326
Peer average EV/Revenue	5.6x	5.6x	5.6x
Dexcom EV/Revenue Premium Over Peers	80.0%	140.0%	190.0%
Dexcom NTM EV/Revenue	10.1x	13.4x	16.2x
Dexcom TEV	\$43,606	\$58,141	\$70,254
Subtract: Net debt	\$130	\$130	\$130
Implied Equity Value	\$43,476	\$58,011	\$70,124
Shares Outstanding	386.0	386.0	386.0
Implied Share Price	\$112.63	\$150.29	\$181.67
Current Share Price	133.34	133.34	133.34
Implied Upside/(Downside)	(15.5%)	12.7%	36.2%